ARGX
argenx SE Healthcare - Biotechnology Investor Relations →
argenx SE (ARGX) closed at $877.72 as of 2026-06-19, trading 60.9% above its 200-week moving average of $545.42. The stock is currently moving closer to the line, down from 64.6% last week. With a 14-week RSI of 71, ARGX is in overbought territory.
Trading volume is running at 1.1x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.93 ratio) is neutral — neither side is clearly dominating.
In 426 weeks of available data, ARGX has never crossed below its 200-week moving average. This suggests the stock has maintained a strong long-term uptrend throughout its history.
With a market cap of $54.9 billion, ARGX is a large-cap stock. The stock trades at 185.4x book value.
Share count has increased 11.7% over three years, indicating dilution.
Over the past 8.2 years, a hypothetical investment of $100 in ARGX would have grown to $995, compared to $320 for the S&P 500. That represents an annualized return of 32.1% vs 15.2% for the index — confirming ARGX as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: ARGX vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
Dislocation Scores Experimental
Each score measures deviation from ARGX's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
ARGX has not crossed below its 200-week moving average in the available data (426 weeks).
Frequently Asked Questions
Is ARGX below its 200-week moving average?
No. argenx SE (ARGX) is currently 60.9% above its 200-week moving average of $545.42. It would need to fall to $545.42 to cross below the line.
What is ARGX's 200-week moving average price?
argenx SE's 200-week moving average is $545.42 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
Is ARGX a good value right now?
Here's what our data says about ARGX as of 2026-06-19: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 71 (overbought). Price-to-book is 185.4x. This is not a buy or sell recommendation — always do your own research.
How does ARGX compare to the S&P 500?
Over the past 8.2 years, $100 invested in ARGX would have grown to $995, compared to $320 for the S&P 500. That's 32.1% annualized vs 15.2% for the index. ARGX has outperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19